These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26123706)

  • 1. How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer.
    van den Anker JN
    Clin Pharmacokinet; 2015 Nov; 54(11):1091-3. PubMed ID: 26123706
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
    Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.
    Völler S; Boos J; Krischke M; Würthwein G; Kontny NE; Boddy AV; Hempel G
    Clin Pharmacokinet; 2015 Nov; 54(11):1139-49. PubMed ID: 25925711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in nano-delivery systems for doxorubicin: an updated insight.
    Kanwal U; Irfan Bukhari N; Ovais M; Abass N; Hussain K; Raza A
    J Drug Target; 2018 Apr; 26(4):296-310. PubMed ID: 28906159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin for metastatic breast cancer: time for a change?
    Muggia F
    Cancer Invest; 2003; 21(6):967-8. PubMed ID: 14735701
    [No Abstract]   [Full Text] [Related]  

  • 7. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
    Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
    J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyphenols, autophagy and doxorubicin-induced cardiotoxicity.
    Shabalala S; Muller CJF; Louw J; Johnson R
    Life Sci; 2017 Jul; 180():160-170. PubMed ID: 28478263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx
    Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Rajamannar T
    Leuk Lymphoma; 2018 Jun; 59(6):1478-1481. PubMed ID: 28994344
    [No Abstract]   [Full Text] [Related]  

  • 11. Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.
    Siebel C; Würthwein G; Lanvers-Kaminsky C; André N; Berthold F; Castelli I; Chastagner P; Doz F; English M; Escherich G; Frühwald MC; Graf N; Groll AH; Ruggiero A; Hempel G; Boos J
    BMC Pharmacol Toxicol; 2020 May; 21(1):37. PubMed ID: 32466789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Size of microspheres after drug loading: perhaps it is time to take a closer look.
    Pua U; Ho BC
    J Vasc Interv Radiol; 2014 Sep; 25(9):1486-8. PubMed ID: 25150910
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
    Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
    J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity.
    Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal doxorubicin.
    Wilkinson K
    Clin J Oncol Nurs; 2002; 6(1):59-61. PubMed ID: 11842492
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.
    Krischke M; Hempel G; Völler S; André N; D'Incalci M; Bisogno G; Köpcke W; Borowski M; Herold R; Boddy AV; Boos J
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1175-1184. PubMed ID: 27770238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
    Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin-Eluting Intra-Arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease.
    Elnekave E; Atar E; Amar S; Bruckheimer E; Knizhnik M; Yaniv I; Dujovny T; Feinmesser M; Ash S
    J Vasc Interv Radiol; 2018 Oct; 29(10):1376-1382. PubMed ID: 30075974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.